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Abstract
Background: Schistosomiasis, caused by infection with the blood fluke Schistosoma, is responsible for greater than 200,000
human deaths per annum. Objective high-throughput screens for detecting novel anti-schistosomal targets will drive
‘genome to drug’ lead translational science at an unprecedented rate. Current methods for detecting schistosome viability
rely on qualitative microscopic criteria, which require an understanding of parasite morphology, and most importantly,
must be subjectively interpreted. These limitations, in the current state of the art, have significantly impeded progress into
whole schistosome screening for next generation chemotherapies.
Methodology/Principal Findings: We present here a microtiter plate-based method for reproducibly detecting
schistosomula viability that takes advantage of the differential uptake of fluorophores (propidium iodide and fluorescein
diacetate) by living organisms. We validate this high-throughput system in detecting schistosomula viability using auranofin
(a known inhibitor of thioredoxin glutathione reductase), praziquantel and a range of small compounds with previously-
described (gambogic acid, sodium salinomycin, ethinyl estradiol, fluoxetidine hydrochloride, miconazole nitrate,
chlorpromazine hydrochloride, amphotericin b, niclosamide) or suggested (bepridil, ciclopirox, rescinnamine, flucytosine,
vinblastine and carbidopa) anti-schistosomal activities. This developed method is sensitive (200 schistosomula/well can be
assayed), relevant to industrial (384-well microtiter plate compatibility) and academic (96-well microtiter plate compatibility)
settings, translatable to functional genomics screens and drug assays, does not require a priori knowledge of schistosome
biology and is quantitative.
Conclusions/Significance: The wide-scale application of this fluorescence-based bioassay will greatly accelerate the
objective identification of novel therapeutic lead targets/compounds to combat schistosomiasis. Adapting this bioassay for
use with other parasitic worm species further offers an opportunity for great strides to be made against additional
neglected tropical diseases of biomedical and veterinary importance.
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Introduction
Infection with the parasitic trematode Schistosoma mansoni causes
a wide range of quantifiable clinical pathologies [1], which
collectively lead to the death of approximately 200,000 individ-
uals/annum [2]. Recent ‘first pass’ description of this parasite’s
genome [3], as well as multiple reports describing the utilization of
numerous functional genomics tools (e.g. [4,5]), have now
provided the technological framework for a renaissance in drug
target and vaccine discovery research [6]. A major bottleneck in
converting schistosome phenotypic discovery into applied thera-
peutic products, however, is the lack of appropriate methods for
quantifying, in a high-throughput manner, individual gene
function or small compound effect on parasite survival. Therefore,
development of reproducible, non-subjective methods for high-
throughput screening of parasite viability would present the
schistosome community with a tangible opportunity to translate
genomic and functional genomics information into therapeutic
strategies to combat schistosomiasis.
Current methods utilized to assess schistosome and other
trematode viability have recently been reviewed [7]. All involve
microscopic techniques where the experimenter manipulates the
parasite in vitro and assesses the effect of such manipulation by bright-
field examination of morphology. This technique has been employed
in immunological studies [8], RNA interference (RNAi) assays [9],
drug screening protocols [9,10] and general manipulations of parasite
development [11]. Criteria used to assess schistosome viability in
these investigations include intracellular granularity, parasite move-
ment, parasite shape alterations and uptake of various vital dyes (e.g.
methylene blue or toluidine blue). The subjective nature of these
various and time-consuming measurement indices indicate that inter-
laboratory estimates of schistosome viability in response to in vitro
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manipulation will be quite variable, resulting in a lack of uniform
reporting within the community.
We report here on an improved methodology to objectively
detect parasite survival during in vitro culture. The fundamental
principle of this assay is derived from the differential membrane
permeability of two well-known dyes, fluorescein diacetate (FDA,
an esterase substrate) and propidium iodide (PI, a DNA
intercalating agent). Based on previously described uses of these
two dyes [12], it was anticipated that FDA would cross the
membranes of living cells (within living schistosomes) and be
converted into highly-fluorescent and charged fluorescein (which
cannot readily leave live cells) by parasite esterase activity. In
contrast to FDA, PI would not be able to cross the membranes of
living parasites and could only stain nucleic acids if there was a
breach in membrane permeability (due to parasite death). In dead
parasites, we hypothesized that PI, and not FDA, would
preferentially stain the assayed sample and, thus, changes in both
dye’s fluorescent intensities would be indicative of schistosome
viability, which could subsequently be quantified by a plate reader,
fluorescent microscope or any device equipped to measure
fluorescence. This single property (simultaneous detection of both
PI and FDA measures) has allowed us to develop a fluorescence-
based, microtiter-plate bioassay to improve detection of schisto-
some viability, which is high-throughput (96- and 384-well
capacity), quantitative and provides objective readouts (fluores-
cence intensity units) of parasite survival during in vitro culture.
Using this flexible bioassay, we demonstrate its versatility in
detecting schistosome survival in response to thioredoxin glutathione
reductase (TGR) inhibition [9]. Furthermore, we adopt this assay to
provide quantitative estimates of schistosome viability in the presence
of recently identified small compounds with previously described [10]
and unknown [3] chemotherapeutic activities. Implementation of this
novel screening platform by academia and industrial stakeholders will
enable inter-laboratory comparisons of in vitro parasite manipulations
to be routinely and quickly performed, vastly accelerating the search
for novel anti-schistosomal lead targets.
Methods
Schistosomula preparation and culturing
Schistosoma mansoni (Puerto Rican strain) infected Biomphalaria
glabrata snails were provided by Fred Lewis (Biomedical Research
Institute, Rockville, MD, USA). Cercariae were shed from infected
snails by exposure to light (60 min at room temperature, RT) and
subsequently converted to schistosomula by mechanical transfor-
mation [13]. Schistosomula were purified away from cercarial tails
by centrifugation through a 60% percoll gradient [14]. Microscope
examination was used to assess the quantity and quality of purified
schistosomula. Schistosomula were cultured at 37uC in T25 tissue
culture flasks containing 9 ml DMEM (Dulbecco’s Modified Eagle
Medium, Sigma-Aldrich), lacking phenol red but containing
4500 mg/l glucose, supplemented with 10% foetal calf serum,
2 mM L-glutamine, 200 U/ml penicillin, 200 mg/ml streptomycin
(all Sigma-Aldrich) in an atmosphere of 5% CO2 for 24 hr before
any further experimental manipulations proceeded. Negligible
parasite death occurred in this media during the 24 hr culturing
period. Following this, schistosomula were aliquoted into black-
sided, flat-bottom (optically clear), 96-well microtiter plates (Fisher
Scientific) in 200 ml media or black-sided, flat-bottom (optically
clear), 384-well microtiter plates (Matrix) in 40 ml media.
Heat killed schistosomula were also prepared by incubating the
24 hr cultivated parasites at 65uC for 10 min. These dead
schistosomula were allowed to cool to 37uC before being used in
subsequent experiments.
Microscopy
Live and heat killed schistosomula stained with optimal
concentrations (empirically derived from [12]) of propidium iodide
(PI, 2.0 mg/ml; Sigma-Aldrich), fluorescein diacetate (FDA, 0.5 mg/
ml; Sigma-Aldrich) or both fluorophores were visualized at6100
magnification using a Leica Axioplan microscope equipped with
FITC (494 excitation) and Rhodamine (536 excitation) filters and a
mercury vapor light source. A Hamamatsu CA74295 camera with
Wasabi Version 1.4 software was used to capture photographic
images of stained schistosomula.
Schistosomula, co-incubated with test compounds, were fluor-
escently visualized as above or unstained at 6100 magnification
using an Olympus CK2 inverted microscope equipped with a
stage extension plate and specimen holder for handling microtiter
plates. A Kodak EasyShare DX7440 digital camera was used to
capture images of unstained schistosomula.
Compound storage, handling and schistosomula
screening
All compounds were purchased from Sigma-Aldrich and included:
gambogic acid, sodium salinomycin, ethinyl estradiol, fluoxetidine
hydrochloride, bepridil, ciclopirox, miconazole nitrate, chlorproma-
zine hydrochloride, amphotericin b, niclosamide, rescinnamine,
flucytosine, vinblastine, carbidopa, praziquantel and auranofin.
Stock solutions of all compounds were made up at 1 mM in
appropriate solvents (Dataset S1) and stored at 280uC. All
compounds were added to black-sided, flat-bottom (optically clear),
96-well microtiter plates containing schistosomula (1000 parasites/
well in triplicate) at 10 mM concentrations. Schistosomula were
cultured (as already indicated; 37uC, 5% CO2) in the presence of
each compound for 24 hr before viability levels were assessed.
Schistosomula viability determination in response to test
compounds
After the 24 hr culturing period in the presence of test compounds,
and prior to addition of fluorescent dyes, all schistosomula were
Author Summary
With only one effective drug, praziquantel, currently used to
treat most worldwide cases of schistosomiasis, there exists a
pressing need to identify alternative anthelmintics before
the development of praziquantel-resistant schistosomes
removes our ability to combat this neglected tropical
disease. At present, the most widely adopted methodology
used to identify promising new anti-schistosome com-
pounds relies on time consuming and subjective micro-
scopic examination of parasite viability in response to in
vitro schistosome/compound co-culturing. In our continued
effort to identify novel drug and vaccine targets, we detail a
dual-fluorescence bioassay that can objectively be used for
assessing Schistosoma mansoni schistosomula viability in a
medium or high- throughput manner to suit either
academic or industrial settings. The described methodology
replaces subjectivity with sensitivity and provides an
enabling technology useful for rapid in vitro screens of
both natural and synthetic compound libraries. It is
expected that results obtained from these quantifiable in
vitro screens would prioritize the most effective anti-
schistosomal compounds for follow-up in vivo experimen-
tation. This highly-adaptable dual-fluorescence bioassay
could be integrated with other methods for measuring
schistosome phenotype and, together, be used to greatly
accelerate our search for novel anthelmintics.
Helminth Fluorescent Bioassay
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washed three times to remove test compound and culture media
supplements. Each wash consisted of centrifuging microtiter plates
containing schistosomula at 1006g for 5 min, removal of half the old
culture media and replacement with an equal quantity of fresh
DMEM (lacking phenol red). After washing the parasites, PI and
FDAwere simultaneously added to each well of the microtiter plate to
obtain a final concentration of 2.0 mg/ml and 0.5 mg/ml respectively.
The 96-well microtiter plates, now containing fluorescently
labeled parasites, were subsequently loaded into a BMG Labtech
Polarstar Omega plate reader containing appropriate filters for the
simultaneous detection of PI (544nm excitation/620nm emission)
and FDA (485nm excitation/520nm emission). All fluorescent
values were obtained with the plate reader incubator set at 37uC to
ensure efficient esterase conversion of FDA to fluorescein within
live schistosomula. The plate reader automatically sets the photo
multiplier tube (PMT) gain for each fluorescent dye and this may
slightly vary between experiments. Inclusion of appropriate
control samples (live and dead schistosomula) compensates for
any inter-plate variations in gain settings.
Data handling and statistical analysis
All data were exported into Microsoft Excel for organization and
into Minitab (Version 14) for statistical analyses. A One-Way Analysis
of Variance (ANOVA) followed by post hoc testing with Fisher’s least
significant difference (LSD) was used to detect statistical differences
between treatments. Viability percentages were either: (1) converted
into probits for auranofin dose response curve generation and
calculation of LD50 values or (2) Arcsin transformed in order to
stabilize variances prior to the use of appropriate statistical analyses.
Numbers of live and dead schistosomula in each well of a
microtiter plate were calculated using the following equations:
Live (FDA fluorescence)~
Sample{Negative control
Positive control{Negative control
Dead (PI fluorescence)~
Sample{Media control
Negative control{Media control
‘Samples’ represent fluorescence intensity units collected from
parasites incubated with test compounds. ‘Negative control’
represents fluorescence intensity units collected from parasites
killed with 10mM auranofin or heat shock (10 min incubation at
65uC), while the ‘Positive control’ represents fluorescence intensity
units collected from untreated parasites. ‘Media control’ represents
fluorescence intensity units originating from wells containing only
media (no parasites).
To determine schistosomula viability in response to each test
compound, a second calculation was employed. This normalization
compensated for inter-well variability in schistosomula numbers across
the microtiter plate, and to facilitate accurate viability comparisons
between test compounds from different microtiter plates:
% Viability~
Live (FDA fluorescence)
Dead (PI fluorescence)zLive (FDA fluorescence)
|100
Results
Microscope examination of in vitro transformed
schistosomula
To first determine whether propidium iodide (PI) and
fluorescein diacetate (FDA) could be used individually to detect
dead or live in vitro transformed S. mansoni schistosomula, an initial
fluorophore uptake experiment was performed with parasite
viability assessed by fluorescent microscopy. Here, in vitro
transformed schistosomula, cultured for 24 hr, were either heat
killed at 65uC for 10 min or left undisturbed at physiological
conditions (37uC). Heat-killed parasites were then subsequently
single-stained with PI (2.0 mg/ml) whereas live parasites were
incubated with FDA (0.5 mg/ml). All dead parasites fluoresced
(Fig. 1A, 16 out of 16) when visualized for PI uptake at 536 nm,
Figure 1. Fluorescein diacetate (FDA) and propidium iodide
(PI) can be used to differentially quantify schistosomula
viability. Mechanically-transformed schistosomula were prepared,
heat-killed (dead) or left untreated (live) and stained with FDA, PI or
both fluorophores according to the Methods. Epi-fluorescent and plane
polarized microscopy was used to visualize uptake of fluorophores and
examine schistosomula morphology. (A) Dead schistosomula stained
with PI and detected by a rhodamine filter (536 nm), (B) Dead
schistosomula visualized by polarized light, (C) Live schistosomula
stained with FDA and detected by a FITC filter (494 nm), (D) Live
schistosomula visualized by polarized light (E) Mixtures of dead and live
schistosomula simultaneously stained with PI/FDA and detected by a
rhodamine filter, (F) Mixtures of dead and live schistosomula
simultaneously stained with PI/FDA and detected by a FITC filter, (G)
Differential detection of PI-positive dead and FDA-positive live
schistosomula by superimposition of both 536 nm and 494 nm
epifluorescent spectra, (H) Differential morphology of dead and live
schistosomula detected by polarized light.
doi:10.1371/journal.pntd.0000759.g001
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with corresponding polarized bright field microscopy imaging of
the same schistosomula samples providing morphological confir-
mation of death (i.e. parasites that were uniform in shape and size
and displayed no movement (Fig. 1B)). Furthermore, all live
parasites fluoresced (Fig. 1C, 10 out of 10) when visualized for
FDA uptake at 494 nm, with corresponding polarized bright field
microscopy imaging of the same schistosomula samples providing
visual confirmation of a physiological normal phenotype (i.e.
parasites displaying a variety of shapes and sizes as the result of
movement during in vitro culturing, Fig. 1D). Further quantifica-
tion of fluorophore uptake was performed on four different regions
of slides containing PI stained schistosomula and from five
different regions of slides containing FDA stained schistosomula.
Here 100% of the parasites were stained with either of the two
examined fluorophores (39 out of 39 dead schistosomula were PI
positive and 48 out of 48 live schistosomula were FDA positive),
confirming the utility of the chosen fluorophores for evenly
staining schistosomula (data not shown).
By demonstrating that PI could effectively be used to stain dead
schistosomula and FDA was capable of identifying live parasites, a
further experiment was conducted to determine whether PI and
FDA could simultaneously be used to detect individual live (FDA
positive) and dead (PI positive) in vitro transformed schistosomula
from a mixed population of differentially viable parasites. Here, in
vitro transformed schistosomula, cultured for 24 hr, were either
heat killed at 65uC for 10 min or left undisturbed at physiological
conditions (37uC). Equal numbers of live and dead schistosomula
were mixed, simultaneously stained with PI (2.0 mg/ml) and FDA
(0.5 mg/ml) and examined for the presence or absence of
differential fluorophore emission. Whereas heat-killed schistosom-
ula exhibited strong PI staining (minimal FDA staining),
physiologically normal schistosomula conversely displayed strong
FDA staining (no observable PI staining) (compare Fig. 1E and
Fig. 1F). This differential staining of individual live and dead
parasites was further supported by observations of undetectable
co-localization of PI and FDA signals (within the same cell of an
individual schistosomulum, detectable as a yellow signal), schisto-
somula phenotype and parasite motility as detected by both
fluorescent and polarized bright field microscopy (Fig. 1G
and 1H).
Optimization of fluorophore/schistosomula incubation
time
A critical first parameter in translating these observations of
differential PI and FDA staining of schistosomula to a method that
takes advantage of the high-throughput potential of a microtiter
plate assay (in both 96- and 384- well formats) was to determine
the optimal timeframe that each fluorescent dye should be
incubated with parasite samples to insure maximal reproducible
detection of viability (Fig. 2). Here, in vitro transformed
schistosomula, cultured for 24 hr, were either killed by heat shock
(65uC for 10 min) or left unaltered at physiological culturing
conditions (37uC). Three samples were subsequently derived from
these schistosomula cultures, which included physiologically
normal, untreated parasites (Fig. 2, green line), heat-killed
parasites (Fig. 2, red line) and an equal mixture of physiologically
normal and heat-killed parasites (Fig. 2, brown line). Derived
schistosomula samples (in triplicate) were co-stained with PI
(2.0 mg/ml) and FDA (0.5 mg/ml) and subjected to fluorescent
intensity measurements (BMG Labtech Polarstar plate reader)
every minute for 120 min. Fluorescent intensity values derived
from triplicate wells containing DMEM (lacking phenol red), PI
(2.0 mg/ml) and FDA (0.5 mg/ml) were also obtained over this
timeframe (Fig. 2, dotted line).
Throughout the assayed 120 min timeframe, the three tested
schistosomula samples (regardless of plate format) demonstrated
clear differences in PI fluorescence emission, with the dead parasites
demonstrating the highest PI values, the live parasites demonstrat-
ing the lowest PI values and the mixed population of live and dead
parasites demonstrating intermediate PI values between the
extremes (Figs. 2A and 2B). While statistical significance in
measured PI fluorescent emission continued to increase (i.e.
p,0.05 at 1 min and p,0.001 for any time point after 4 min) with
time for any of the compared schistosomula samples, PI fluorescent
emission differences between physiologically normal schistosomula
(live) and DMEM (lacking phenol red) samples remained small
throughout the duration of the 120-minute timeframe and never
reached statistical significance (p,0.001). Therefore, based on these
analyses, the optimal PI incubation time to distinguish between
dead and live schistosomula is between 4 and 120 min, regardless of
plate format. We chose 20 min to collect PI data as it provided an
adequate time window to process multiple microtiter plates
(indicated in Fig. 2A and 2B) and was well within the calculated
window of accurately being able to determine statistical significance
amongst live and dead schistosomula.
Whereas PI staining of parasite samples yielded differential
fluorescent results over the entire 120-minute timeframe (Fig. 2A
and 2B), FDA staining of live, dead and mixed schistosomula
populations in either 96-well or 384-well microtiter plate formats
generated fluorescent data that quickly reached a plateau (51 min
for 96-well microtiter plates, Fig. 2C and 32 min for 384-well
microtiter plates, Fig. 2D). Therefore, collection of FDA
fluorescence was halted at 51 min. Nonetheless, FDA fluorescent
intensity units measured across these time intervals produced data
as expected with live parasites fluorescing brightest, dead parasites
weakest and mixed live/dead parasite populations intermediate
between the two (Fig. 2C and 2D). Furthermore, differences in
detected FDA fluorescence between any of the three schistosomula
samples (in both microtiter plate formats) were found to be
statistically significant between 3 min and 12 min. However,
unlike the PI timecourse (Fig. 2A and 2B), differences in FDA
fluorescent emission originating from wells containing DMEM
and all schistosomula samples were statistically significant
beginning at 3 minutes (p,0.05). This finding makes DMEM
unsuitable for use as a blank for detecting non-specific FDA
fluorescence. Therefore, based on these analyses, the optimal FDA
incubation time to distinguish between dead and live schistosom-
ula in both microtiter plate formats is between 3 and 12 min. We
chose 5 min (indicated in Fig. 2C and 2D) to collect FDA data in
both microtiter plate formats as this fluorophore is prone to
spontaneous hydrolysis [15].
Determination of assay sensitivity
To determine the sensitivity limits of this fluorescence-based
assay in measuring schistosomula viability in a medium and a high
throughput manner, two different experimental approaches were
considered (Figs. 3 and 4). In the first approach (Fig. 3A–D),
schistosomula were serially diluted (5000 reducing to 36 parasites
for a medium throughput 96-well plate format; 1000 reducing to 8
parasites for a high-throughput 384-well plate format, in triplicate)
to identify the absolute minimum number of parasites that could
be reproducibly detected. Briefly, in vitro transformed schistosom-
ula, cultured for 24 hr, were either heat killed (65uC for 10 min) or
left unaltered at physiological conditions (37uC). After serially
diluting these differentially treated schistosomula samples, FDA or
PI fluorophores were added and measurement of fluorescence
intensity proceeded, within the parameters determined above
(5 min for FDA and 20 min for PI).
Helminth Fluorescent Bioassay
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Correlation analysis revealed a strong linear relationship
between PI fluorescence and dead schistosomula number. For
the 96-well plate format (Fig. 3A) a high correlation (r=0.995)
existed between the measured PI fluorescence and numbers of
dead schistosomula sampled, while for the 384-well plates (Fig. 3B)
a slightly lower correlation (r=0.986) existed between measured PI
fluorescence and numbers of dead schistosomula.
Correlation analysis of FDA fluorescence and live schistosomula
also revealed a strong linear relationship (r=0.952 for the 96-well
plate format, Fig. 3C and r=0.977 for the 384-well format, Fig. 3D),
although the linearity was affected by an FDA-associated fluorescence
plateau effect seen when increased numbers of schistosomula were
assayed. From these experiments, it was determined that optimal
numbers of schistosomula for assays conducted in a 96-well microtiter
plate are between 500 and 2500 parasites per well, while for assays
conducted in a 384-well microtiter plate, optimal numbers of
schistosomula are between 50 and 500 per well.
The second approach used to interrogate the sensitivity of this
fluorescence-based assay for detecting schistosomula viability was
to replicate conditions where varying percentages of live and
dead schistosomula would be found in the same sample (i.e. in
vitro drug assays, where the drug tested is less than 100% efficient
in killing). By mixing different percentages of live (physiologically
normal) and dead (heat killed) parasites (Fig. 4), we tested the
ability of PI (Figs. 4A and 4C) and FDA (Figs. 4B and 4D) to
distinguish viability in a population of 1000 schistosomula in a
96-well plate (Fig. 4E) and 200 schistosomula in a 384-well plate
(Fig. 4F). In both plate formats, intra-well PI fluorescence
decreased and FDA fluorescence increased when greater
percentages of live schistosomula were being examined. This
made it possible to differentially identify schistosomula viability in
intervals of 25% for both 96- and 384-well plate formats.
However, the standard deviations reported for some values
indicated that there was variability inherent in pipetting with
discrete units of this size. The use of a dual staining method was,
therefore, important for counteracting any pipetting errors and
verifying that differences in fluorescence are genuinely caused by
differences in mortality.
Figure 2. A kinetic study of FDA and PI emission reveals the optimal timeframes to collect fluorescent signals from stained
schistosomula samples. Mechanically-transformed schistosomula were cultured for 24 hr, heat killed (dead) or left untreated (live), simultaneously
stained with PI and FDA and subjected to fluorescent readings at minute intervals. PI fluorescence (544 nm) was measured over 120 min whereas
FDA fluorescence (485 nm) was measured over 51 min. (A) PI fluorescence data collected from a 96-well microtiter plate, (B) PI data collected from a
384-well microtiter plate, (C) FDA data collected from a 96-well microtiter plate and (D) FDA data collected from a 384-well microtiter plate. All
fluorescent readings were obtained from a BMG Labtech Polarstar Omega microtiter plate reader. Red lines represent fluorescent data originating
from wells containing dead schistosomula, green lines represent fluorescent data originating from wells containing live schistosomula, brown lines
represent fluorescent data from wells containing an equal number (mixed) of dead and live schistosomula and dotted lines represent fluorescent data
originating from wells containing no schistosomula (media). * Indicates chosen time point for collecting PI data and ¤ indicates chosen time point for
collecting FDA data in subsequent experiments. All experiments were performed at least three times. Schistosomula were plated at 1000 parasites/
well in the 96-well microtiter plate format and 200 parasites/well in the 384-well microtiter plate format.
doi:10.1371/journal.pntd.0000759.g002
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Validation of the dual fluorescent assay for identifying
therapeutic lead compounds
To validate this fluorescent-based viability assay for practical
application in medium to high-throughput drug screening, it was
used to assess the efficacy of a known anti-schistosomula
compound, auranofin (Fig. 5). An inhibitor of parasite thioredoxin
glutathione reductase (TGR), auranofin has been shown (estimat-
ed by light microscopy examination) to be 100% lethal to in vitro
cultured, mechanically-transformed schistosomula at 10 mM
concentrations, 24 hr after treatment [9].
In agreement with published reports, there is a clear and
titratable anti-schistosomula effect mediated by auranofin with the
dual fluorescent staining procedure allowing viability quantifica-
tion of each drug concentration at 24 hours post-treatment
(Fig. 5A). Percent viability transformations into probit values also
allowed an auranofin LD50 of 0.8260.49 to be calculated (Fig. 5B).
Maximum drug effect was seen at 10 mM, where microscopic
examination of schistosomula confirmed that death was 100%
(Fig. 5C, 5E and 5F), when compared to untreated parasites
(Fig. 5D). At an auranofin concentration within the calculated
LD50 range (1 mM), schistosomula contained cells either labeled
with PI or FDA throughout the lophotrochozoan body (Fig. 5G
and 5H). Statistically-significant, auranofin-mediated mortality,
compared to either vehicle treated (DMSO) schistosomula or
untreated parasites (live), was also observed for drug concentra-
tions of 5 mM, 2.5 mM and 1.25 mM.
Further validation of this viability assay was next performed by
assessing the effect of compounds with previously-identified [10] or
suggested anti-schistosomal activities [3] (Fig. 6). These com-
pounds included four (gambogic acid, sodium salinomycin,
niclosamide nitrate and amphotericin b) that have been described
to induce schistosomula mortality [10], three (ethinyl estradiol,
fluoxetine hydrochloride and chlorpromazine hydrochloride) that
have been reported to induce schistosomula over-activity [10], two
(miconazole nitrate and praziquantel) that have been shown to
produce a shape alteration (‘rounded’ phenotype) [10] and six
(bepridil, ciclopirox, rescinnamine, flucytosine, vinblastine and
carbidopa) that have never been tested on schistosomula [3] (full
details in Dataset S1). Of the tested compounds with previously-
recorded effects on schistosome phenotypes [10], our dual-
fluorescent viability screen, reassuringly showed broad agreement
(Fig. 6A). Here, the compounds previously described as inducing
Figure 3. A schistosomula titration series reveals the optimal number of parasites to be used for PI and FDA fluorescent detection
in both 96-well and 384-well microtiter plates. Mechanically-transformed schistosomula were cultured for 24 hr, heat killed (dead) or left
untreated (live) and stained with either PI (dead parasites) or FDA (live parasites). (A) Dead schistosomula were titrated from 5000 to 36 parasites per
well (in triplicate) in a 96-well microtiter plate and PI fluorescence (544 nm) obtained at 20 min, (B) Dead schistosomula were titrated from 1000 to 8
parasites per well (in triplicate) in a 384-well microtiter plate and PI fluorescence (544 nm) obtained at 20 min, (C) Untreated, live schistosomula were
titrated from 5000 to 36 parasites per well (in triplicate) in a 96-well microtiter plate and FDA fluorescence (485 nm) measured at 5 min, (D)
Untreated, live schistosomula were titrated from 1000 to 8 parasites per well (in triplicate) in a 384-well microtiter plate and FDA fluorescence
(485 nm) measured at 5 min. All fluorescent readings were collected from a BMG Labtech Polarstar Omega microtiter plate reader. These results are
representative of two independent experiments.
doi:10.1371/journal.pntd.0000759.g003
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Figure 4. Dual FDA and PI staining of schistosomula samples allows for fluorescent quantification of parasite viability.
Mechanically-transformed schistosomula were cultured for 24 hr, heat killed (dead) or left untreated (live), distributed into wells at pre-defined
percentages (100% live, 75% live, 50% live, 25% live 0% live) and simultaneously stained with PI and FDA. (A) Pre-defined percentages of live and
dead schistosomula (1000 parasites per well, in triplicate) distributed into a 96-well microtiter plate with PI fluorescence (544 nm) measured at
20 min, (B) Pre-defined percentages of live and dead schistosomula (1000 parasites per well, in triplicate) distributed into a 96-well microtiter plate
with FDA fluorescence (485 nm) measured at 5 min, (C) Pre-defined percentages of live and dead schistosomula (200 parasites per well, in
triplicate) distributed into a 384-well microtiter plate with PI fluorescence (544 nm) detected at 20 min, (D) Pre-defined percentages of live and
dead schistosomula (200 parasites per well, in triplicate) distributed into a 384-well microtiter plate with FDA fluorescence (485 nm) detected at
5 min. (E) Schistosomula viability calculated from fluorescent data displayed in A and B, (F) Schistosomula viability calculated from fluorescent data
presented in C and D. Formula for viability calculations is indicated in the Methods section. These results are representative of experiments
performed three times.
doi:10.1371/journal.pntd.0000759.g004
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Figure 5. Dual-fluorescence viability determination of auranofin treated schistosomula. Mechanically-transformed schistosomula were
cultured for 24 hr, incubated with different concentrations of auranofin for an additional 24 hr, washed and subsequently co-stained with both PI and
FDA. PI- (544 nm, collected at 20 min) and FDA- (485 nm, collected at 5 min) fluorescence intensity units were converted into viability measures
according to the formula described in the Methods. (A) Dose-dependent anti-schistosomula effect of auranofin as indicated by % viability. Treatments
showing statistically significant differences in viability when compared to untreated (live) schistosomula are indicated with * (p,0.05) or ** (p,0.001).
(B) Auranofin dose-response curve by which an LD50 was calculated by plotting the probit transformation of the % viability to the Log10
transformation of auranofin concentration. Dotted line indicates the average LD50 value calculated from three replicates. (C) Light microscope image
of schistosomula treated with 10mM auranofin for 24 hr. (D) Light microscope image of untreated schistosomula. (E) Epi-fluorescent and (F) plane
polarized light micrograph of schistosomula treated with 10mM auranofin for 24 hr, then incubated with both PI and FDA. (G) Epi-fluorescent and (H)
plane polarized light micrograph of schistosomula treated with 1mM auranofin for 24 hr, then incubated with PI and FDA. ‘Dead’ represents
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an over-active (ethinyl estradiol, fluoxetine hydrochloride and
chlorpromazine hydrochloride) or rounded (miconazole nitrate
and praziquantel) phenotype, as expected, did not affect
schistosomula viability. Fluorescent readings obtained from wells
containing parasites treated with these compounds were no
different from wells containing untreated parasites (average
viability 84.3%, data not shown). Microscopic examination of
these treated parasites confirmed their viability (e.g. Fig. 6E and
Figure S1). However, only two of four previously defined anti-
schistosomula compounds (gambogic acid and amphotericin b)
induced measurable death as determined by our dual-fluorescent
viability assay (confirmed by microscopic examination of schisto-
somula, e.g. Fig. 6B and Fig. S1). Sodium salinomycin and
niclosamide produced fluorescent viability measurements similar
to those derived from untreated parasites. Detailed microscopic
examination of schistosomula treated with sodium salinomycin
demonstrated that the parasites were strongly FDA positive (with
some PI positive cells) (Fig. 6C), dark and granular (Fig. 6H and
Figure S1, panel B), but motile (Figure S1, panel B) whereas
niclosamide treated schistosomula appeared morphologically
(Fig. 6I and Figure S1, panel H) and fluorescently (Fig. 6D)
similar to praziquantel treated parasites (rounded phenotype,
Fig. 6E, Fig. 6J and Figure S1, panel I). Of the six compounds with
an unknown, but suggested, anti-schistosome effect, none showed
strong decreases in viability as determined by the dual fluorescence
assay or epifluorescent microscopy (e.g. ciclopirox, Fig. 6F) under
the conditions tested in this study. However, upon further
microscopic examination, some compounds did induce shape
alterations in schistosomula phenotype (e.g. ciclopirox, Fig. 6K
and Figure S1, panel K).
Discussion
In this study we detail the development and validation of a novel
medium- to high- throughput microtiter assay for assessing
viability in the schistosomula stage of the human parasite S.
mansoni. Infection with this parasitic trematode leads to chronic
pathology in endemic populations accounting for disability
adjusted life year (DALYs) estimates surpassing malaria or
tuberculosis [16], and is responsible for approximately 200,000
deaths per annum [2]. With only one drug (praziquantel)
predominantly used to treat this disease, the potential for drug
resistant parasite strains poses a real threat to global control
initiatives [17] and supports the vital need for identifying novel
therapeutic drug classes or bioactive molecules. To date, high-
throughput discovery of new and effective anti-schistosomal
compounds has been hampered by the lack of a uniform and
quantifiable evaluation method, with current assessment of
trematode viability involving subjective and labor-intensive
microscopic examination [7]. Application of improved and
objective methods in detecting schistosome viability will, therefore,
greatly enhance the discovery of next generation chemotherapeu-
tic agents. Here, we provide evidence that a dual-fluorescent,
whole schistosomula bioassay (helminth fluorescent bioassay; HFB)
contains many criteria required for successful high-throughput
screening and demonstrate an easily-adaptable methodology by
which the Schistosoma genomes [3,18] can be rapidly screened for
urgently needed drug targets.
While many fluorophores are available for use in viability
measurements, propidium iodide (PI) and fluorescein diacetate
(FDA) were initially chosen due to their distinct wavelength
emission profiles, wide availability from suppliers and low cost.
These criteria and the experimental validation that individual
schistosomula of polarized viability (either dead or alive) only
fluoresced red (PI positive or dead) or green (FDA positive or alive)
and not yellow (Fig. 1), indicated that these two fluorophores
stained schistosomula cells independently and could inexpensively
be used to quantify parasite viability, when applied to methodol-
ogy involving a microtiter plate reader equipped to detect
fluorescence. While variation in fluorophore (both PI and FDA)
uptake was noticeable amongst individual schistosomula (Fig. 1),
this was expected due to the non-synchronous nature of
schistosome development in vitro as well as experimental factors
that commonly affect epifluorescent microscopy including focal
point differences between individuals, imperfections in the glass
coverslip, localization of a parasite near an air bubble or digital
processing of captured images. Importantly, these factors did not
interfere with the acquisition of highly-reproducible fluorescence
collected from a population of assayed schistosomula when
measured by a plate reader (i.e. Figs. 2–4). Taken together, PI
and FDA contained multiple characteristics well-suited for
detection of schistosomula viability and, therefore, adapting these
fluorophores to microtiter plate formatting was pursued.
While minor differences existed between plate formats (Figs. 2, 3
and 4A–D; 96- versus 384-well), these did not affect the overall
quantification of schistosomula viability (Fig. 4E vs 4F). For
example, due to smaller surface areas within wells of a 384-well
microtiter plate (compared to 96-well microtiter plates), fluorescent
intensity slopes (when correlated to parasite number, Fig. 3 or
parasite viability, Fig. 4A–D) were not as steep when compared to
fluorescent intensity measurements collected from 96-well micro-
titer plates. Nevertheless, strong correlation coefficients, compar-
ing fluorescent intensity units with schistosomula number (Fig. 3),
were obtained in both microtiter plate formats. From these
experiments, it was also apparent that FDA could be subjected to
spontaneous hydrolysis (Fig. 2C and 2D). While this has been
documented before in other systems [15], and could be due to
media components or residual esterase activity released by the
dead schistosomes, the fluorescence measured between live and
dead parasites were sufficiently large to detect a significant
difference (between 3 min and 12 in both 96-well and 384-well
plate formats). Nevertheless, substitution fluorophores for FDA,
including calcein AM and sulfofluorescein diacetate, are being
investigated in current optimizations to the HFB.
The observation that calculated, intra-well schistosomula
viability (mathematically derived from plate reader measurements
of both PI and FDA, Fig. 4A–D) paralleled the proportion of
viable schistosomula dispensed into each well (Fig. 4E and 4F),
demonstrated that FDA and PI could cooperatively be used to
sensitively and accurately differentiate amongst percentages of
viable parasite populations within either 96- or 384- well
microtiter plate formats. This is essential as any high-throughput
anthelmintics screening assay may include compounds that do not
induce 100% schistosomula lethality and, therefore, use of both PI
and FDA allow for accurate quantification across a range of
viability endpoints (between 0% viable to 100% viable).
Taking advantage of PI and FDA’s cooperative ability to
differentially stain schistosomula and the capability of a microtiter
plate reader to sensitively quantify inter-well parasite viability, we
applied the HFB to compounds previously shown to affect
schistosomula killed by heat-treatment and ‘0 mM’ auranofin represents schistosomula incubated with 1% (v/v) DMSO (auranofin solvent). These
results are representative of experiments performed three times.
doi:10.1371/journal.pntd.0000759.g005
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Figure 6. Application of the dual-fluorescent viability assay for determining the anti-schistosomula effect of selected compounds with
previously-described or unknown activities.Mechanically-transformed schistosomula were cultured for 24 hr, incubated with compounds (10 mM)
for an additional 24 hr, washed and subsequently co-stained with both PI and FDA. PI- (544 nm, collected at 20 min) and FDA- (485 nm, collected at
5 min) fluorescence intensity units were converted into viability measures according to the formula described in the Methods. (A) Calculated
schistosomula viability in response to each compound tested (further details can be found in Dataset S1). Representative epi-fluorescent and plane
polarized microscope images of schistosomula treated with (B and G) gambogic acid, (C and H) sodium salinomycin, (D and I) niclosamide, (E and J)
praziquantel and (F and K) ciclopirox are indicated. Compounds designated as having ‘previously published activities’ (grey histograms – death, vertical
lines within histograms – overactive, hatched lines within histograms – rounded) were selected from those described by Abdulla et al. [10] while those
compounds indicated as having ‘unknown activities’ (black histograms) were selected from Berriman et al. [3]. These results are representative of two
independent experiments.
doi:10.1371/journal.pntd.0000759.g006
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schistosomula phenotype and survival [9,10]. The first compound
selected was auranofin, a potent thioredoxin glutathione reductase
inhibitor that has previously been shown to kill larval schistosom-
ula and adult schistosomes [9]. While our HFB confirmed that
auranofin does induce schistosomula death (Fig. 5), our results
additionally demonstrated a much finer sensitivity in detecting
auranofin LD50 levels (concentration of auranofin that kills 50% of
the assayed biological material). Kuntz et al. [9], using microscopy,
reported LD50 levels of auranofin on schistosomula to be between
2 mM and 5 mM. Our auranofin titration series, detected by
fluorescent-based microtiter plate quantification, demonstrated
that this compound has an anti-schistosomula LD50 activity of
0.82 mM60.49 mM. This objective determination is approximate-
ly 4 fold more sensitive than what was previously published and
clearly demonstrates the increased sensitivity of the HFB and a
standardized methodology. Interestingly, schistosomula, treated
with 1 mM auranofin (within the calculated LD50 range) and
visualized by epifluorescent microscopy, displayed cells that were
stained with either PI or FDA throughout the body (Fig. 5G). This
finding clearly indicates that the HFB is sensitive enough to detect
compound-induced changes in fluorescence affecting different cell
populations within individual schistosomula as well as between
schistosomula and may be useful in identifying compounds that
induce cellular stress (in addition to whole organism viability).
We next expanded use of the HFB to verify the activity of
selected compounds on schistosome phenotype and viability as
previously demonstrated by Abdulla et al. [10]. Two of the nine
compounds screened showed variance with the published results.
The first of these, sodium salinomycin, in contrast to previously
published observations [10], did not induce schistosomula lethality
when measured by the HFB or epifluorescent microscopy (Fig. 6A
and 6C). The other compound tested that gave conflicting results
to that which were published is niclosamide. Niclosamide is
recorded in the literature as an anthelmintic, however, its use as
such is mainly against cestodes [19] with anti-trematode activity
only being reliably recorded against immature Paramphistomum spp.
[20]. Its use in schistosomiasis control seems to be limited as a
moluscicide for control of the intermediate snail host (e.g [21]).
While both sodium salinomycin and niclosamide treated schisto-
somula were stressed (decrease in motility - sodium salinomycin,
Fig. 6H; shape alterations – niclosamide, Fig. 6I; some PI positive
cells – both compounds, Figs. 6C and 6D), it is not clear why our
results differ from Abdulla et al. [10] in relationship to measured
viability. A likely explanation may be associated with how the
schistosomula were processed before drug treatment in the two
studies. While our study utilized schistosomula, cultured at 37uC,
24 hr after mechanical transformation, Abdulla et al. used
schistosomula, maintained on ice, 2 hr after mechanical transfor-
mation [10]. We propose that schistosomula, maintained at 4uC,
are likely to be more physiologically stressed than parasites
cultured at 37uC and, therefore, more susceptible to additional
manipulations such as drug treatment. These differences in
schistosomula processing, as well as the fact that alternative
solvents for niclosamide and sodium salinomycin were used
(ethanol and acetone in this study, whereas DMSO in Abdulla
et al. [10]), could likely explain the observed differences.
The final application of the HFB for measuring schistosomula
viability was directed towards the verification of potential novel
anthelmintics from those identified by the chemogenomics
screening strategy outlined in the recent publication of the S.
mansoni genome [3]. Using an iterative bioinformatics approach,
Berriman et al. identified 26 S. mansoni target proteins that have
strong orthology to human proteins currently being targeted by
approved drugs [3]. It was suggested that ‘drug-repositioning’
strategies that re-use existing drugs offer potential savings and cost
benefits to the development of novel anthelmintics, especially in
the context of neglected tropical diseases like schistosomiasis.
Therefore, six drugs with activity against human proteins (bepridil -
calmodulin, ciclopirox - deoxyhypusine synthase, rescinnamine –
vesicular amine transporter, flucytosine – bifunctional dihydrofolate
reductase-thymidylate synthase, vinblastine – beta tubulin and
carbidopa – aromatic amino acid decarboxylase) were tested against
the Schistosoma orthologs (Smp_026560, Smp_065120, Smp_
121920, Smp_135460, Smp_030730 and Smp_171580 respective-
ly) using the HFB (Fig. 6A). While none of the selected drugs
showed any notable effect on schistosomula viability (at 10 mM),
some induced phenotypic changes in parasite morphology
(Fig. 6K and S1) and caused a degree of physiological stress
(some PI positive cells, Fig. 6F). These compounds, like sodium
salinomycin and niclosamide (see above) warrant further
investigations. The most likely explanation for lack of any
detectable anthelmintic activity is that the tested drugs could not
efficiently cross the heptalaminate membrane covering the newly
transformed schistosomula or that the target proteins were not
highly expressed in this larval life stage. Efforts to increase the
membrane permeability of all tested drugs (i.e. standardized
solubilization in DMSO) are currently being implemented in
current screens of schistosomula viability, which likely will
decrease this potential confounding factor.
Recently, both Smp_121920 (vesicular amine transporter) and
Smp_135460 (bifunctional dihydrofolate reductase-thymidylate
synthase) were found to be minimally expressed in the schisto-
somula lifecycle stage as determined by DNA microarray analysis
of the parasite lifecycle [22]. These gene expression results could
explain the ineffective anti-schistosomula nature of rescinnamine
and flucytosine. However, in the same study [22], Smp_026560
(calmodulin) was abundantly found in newly-transformed schisto-
somula. This finding, supported by proteomic analyses of
schistosomula [23,24] indicates that calmodulin would be in
sufficient quantities for targeting by bepridil. Therefore, although
presence of schistosomula targets is necessary for measuring drug
effectiveness, it is not sufficient. Other factors (e.g. drug
biotransformation and drug synergy) are equally important and
should be carefully considered during the interpretation of anti-
schistosomula drug screening results.
In summary, we report a methodology that enables the
objective measurement of schistosomula viability, which is
quantitative, fast and inexpensive. Although we have restricted
its application to drug assays, the adapted methodology has the
potential to be used for assessing viability during high-throughput
RNAi screens and general manipulations of schistosome develop-
ment. With this assay functioning in both 96- or 384-well
microtiter plate formats, it can be readily adapted for use in
academic or industrial settings, in particular if robotics or semi-
automation were available. Further refinements of the assay could
be proposed to increase processivity and facilitate adaptation to
other parasitic and non-parasitic worm species. As well as other
worm species, the HFB should also be applicable to other
Schistosoma lifecycle stages, including the adult and this enhance-
ment is among other modifications currently being pursued. As
death is not the only criterion that could be measured when
assessing potential anthelmintic compounds (compounds that
induce stress, paralysis or shape alterations are equally likely to
be potent; e.g. niclosamide, sodium salinomycin, ciclopirox, etc.),
we are currently integrating phenomics, metabolomics and high
content screening approaches to add value to our HFB. The
combined use of these multiple and quantifiable methods to
describe a compound’s effect on helminth development will
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exponentially increase the number of preliminary hits translated
into effective and novel anthelmintic chemotherapies.
Supporting Information
Dataset S1 Further description of selected compounds used in
the dual-fluorescent helminth viability assay.
Found at: doi:10.1371/journal.pntd.0000759.s001 (0.01 MB XLS)
Figure S1 Light microscope images of schistosomula treated
with each of the test compounds. Mechanically-transformed
schistosomula were cultured for 24 hr, incubated with compounds
(10 mM) for an additional 24 hr, washed and photographed
according to Methods. (A) Gambogic acid, (B) Sodium Salinomy-
cin, (C) Ethinyl estradiol, (D) Fluoxetine hydrochloride, (E)
Miconazole nitrate, (F) Chlorpromazine hydrochloride, (G)
Amphiotericin B, (H) Niclosamide, (I) Praziquantel, (J) Bepridil,
(K) Ciclopirox, (L) Rescinnamine, (M) Flucytosine, (N) Vinblas-
tine, (O) Carbidopa.
Found at: doi:10.1371/journal.pntd.0000759.s002 (7.61 MB TIF)
Acknowledgments
We thank Dr. Fred Lewis at the Biomedical Research Laboratory for
provision of infected snails, Ms Julie Hirst for snail husbandry and Drs.
Steven Wade and Glynn Jenkins for assistance with fluorescent microscopy.
We also thank Dr. Hazel Wright for assistance with statistical analyses, Ms
Kate Martin for general advice on bioassay development and Dr. Rhian
Hayward for critically reviewing this manuscript.
Author Contributions
Conceived and designed the experiments: EP IWC KFH. Performed the
experiments: EP. Analyzed the data: EP. Wrote the paper: EP IWC KFH.
References
1. King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic
helmintic infection: a meta-analysis of disability-related outcomes in endemic
schistosomiasis. J Lancet 365: 1561–1569.
2. Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH (2003) Drugs for
the control of parasitic diseases: current status and development in schistoso-
miasis. Trends Parasitol 19: 509–515.
3. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, et al. (2009) The
genome of the blood fluke Schistosoma mansoni. Nature 460: 352–358.
4. Brindley PJ, Pearce EJ (2007) Genetic manipulation of schistosomes. Int J for
Parasitol 37: 465–473.
5. Hokke CH, Fitzpatrick JM, Hoffmann KF (2007) Integrating transcriptome,
proteome and glycome analyses of Schistosoma biology. Trends Parasitol 23:
165–174.
6. Colley DG, Secor WE (2007) A schistosomiasis research agenda. PLoS Negl
Trop Dis 1: e32.
7. Keiser J (2009) In vitro and in vivo trematode models for chemotherapeutic
studies. Parasitology 137: 589–603.
8. Hoffmann KF, James SL, Cheever AW, Wynn TA (1999) Studies with double
cytokine-deficient mice reveal that highly polarized Th1-and Th2-type cytokine
and antibody responses contribute equally to vaccine-induced immunity to
Schistosoma mansoni. J Immunol 163: 927.
9. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, et al. (2007)
Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential
Parasite Enzyme and a Key Drug Target. PLoS Medicine 4: e206.
10. Abdulla MH, Ruelas DS, Wolff B, Snedecor J, Lim KC, et al. (2009) Drug
Discovery for Schistosomiasis: Hit and Lead Compounds Identified in a Library
of Known Drugs by Medium-Throughput Phenotypic Screening. PLoS Negl
Trop Dis 3: e478.
11. Gold D (1997) Assessment of the viability of Schistosoma mansoni schistosomula by
comparative uptake of various vital dyes. Parasitol Res 83: 163–169.
12. Jones K, Senft J (1985) An improved method to determine cell viability by
simultaneous staining with fluorescein diacetate-propidium iodide. J Histochem
Cytochem 33: 77–79.
13. Colley DG, Wikel SK (1974) Schistosoma mansoni: simplified method for the
production of schistosomules. Exp Parasitol 35: 44–51.
14. Lazdins JK, Stein MJ, David JR, Sher A (1982) Schistosoma mansoni: rapid
isolation and purification of schistosomula of different developmental stages by
centrifugation on discontinuous density gradients of Percoll. Exp Parasitol 53:
39.
15. Clarke JM, Gillings MR, Atlavilla N, Beattie AJ (2001) Potential problems with
fluorescein diacetate assays of cell viability when testing natural products of
antimicrobial activity. J Microbiol Methods 46: 261–267.
16. King CH, Dangerfield-Cha M (2008) The unacknowledged impact of chronic
schistosomiasis. Chronic Illn 4: 65.
17. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, et al. (2009)
Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and
current research needs. Parasitology 136: 1825–1835.
18. Zhou Y, Zheng H, Chen Y, Zhang L, Wang K, et al. (2009) The Schistosoma
japonicum genome reveals features of host–parasite interplay. Nature 460:
345–351.
19. Tanowitz HB, Weiss LM, Wittner M (1993) Diagnosis and treatment of
intestinal helminths. I. Common intestinal cestodes. Gastroenterologist 1:
265–273.
20. Harder A (2002) Chemotherapeutic approaches to trematodes (except
schistosomes) and cestodes: current level of knowledge and outlook. Parasitol
Res 88: 587–590.
21. Coura-Filho P, Mendes NM, Souza CP, Pereira JP (1992) The prolonged use of
niclosamide as a molluscicide for the control of Schistosoma mansoni. Rev Inst Med
Trop Sa˜o Paulo 34: 427–431.
22. Fitzpatrick JM, Peak E, Perally S, Chalmers IW, Barrett J, et al. (2009) Anti-
schistosomal Intervention Targets Identified by Lifecycle Transcriptomic
Analyses. PLoS Negl Trop Dis 3: e543.
23. Curwen RS, Ashton PD, Johnston DA, Wilson RA (2004) The Schistosoma
mansoni soluble proteome: a comparison across four life-cycle stages. Mol
Biochem Parasitol 138: 57–66.
24. Knudsen GM, Medzihradszky KF, Lim KC, Hansell E, McKerrow JH (2005)
Proteomic analysis of Schistosoma mansoni cercarial secretions. Mol Cell
Proteomics 4: 1862–1875.
Helminth Fluorescent Bioassay
www.plosntds.org 12 July 2010 | Volume 4 | Issue 7 | e759
